The field of protein engineering is at an exciting point in its development, with new generations of therapeutic antibodies now reaching the market, great advances in protein science and a body of clinical evidence that can be used to inform the development of safe, highly effective therapies for unmet medical needs.  At PEGS, Engineering Antibodies presents the state of the art in technologies used by protein engineers working at the discovery and design stage to quickly and efficiently craft biotherapeutics directed at the most elusive targets and biological functions.  Emphasis will be given to new presentations that highlight unpublished work in this important field.

Topics will include, but are not limited to:

Protein Engineering to Improve the Targeting of Antibody Therapeutics

  • Cell-penetrating peptides
  • Crossing the blood-brain barrier
  • Engineering uptake mechanisms for the cytosolic delivery of binding proteins
  • Immunotoxins to improve binding specifically to target cells
  • T cell directing bispecifics

Discovery of Novel Antibodies

  • Antigen-specific cell sorting technologies for antibody discovery
  • Computational and structural approaches to target discovery and biotherapeutic design
  • Next generation antibody discovery libraries
  • Next generation immunizations
  • Translational research models for improved antibody discovery

Selection and Screening

  • Antigenicity as a screening criteria
  • Deep sequencing of antibody selections
  • How structural features contribute to selection
  • In vivo antibody selection methodologies
  • Novel methods for screening large repertoires

Emerging Indications for Antibody Therapeutics

  • Bispecific antibodies for tissue targeting in metabolic diseases
  • Clinical experiences with PCSK9 inhibitors for cholesterol lowering
  • Development of broadly neutralizing antibodies for HIV and flu indications
  • Improving the efficacy of antibody therapeutics in inflammatory diseases
  • Targeting GPCRs and ion channels with antibody therapeutics

Other Technologies

  • Development of tri-specific and tetra-specific antibodies
  • Engineering immunomodulatory proteins
  • Matching appropriate effector function to disease
  • Practical applications of structural biology in protein engineering
  • Regulatory justification for antibodies with challenging safety profiles

Scientists who wish to present their knowledge and expertise to their colleagues are asked to click here to submit an abstract.  Remember to specify the conference that you are interested in and please provide your full contact information.

Deadline for submission is Friday, September 25, 2015

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

For more details on the conference, please contact:

For partnering and sponsorship information, please contact:

Kent Simmons
Senior Conference Director
Cambridge Healthtech Institute
Phone: 207-869-9199
E-mail: ksimmons@healthtech.com

Jason Gerardi
(Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: 781-972-5452
E: jgerardi@healthtech.com

Carol Dinerstein
(Companies L-Z)
Director, Business Development
Cambridge Healthtech Institute
T: 781.972.5471
E: dinerstein@healthtech.com